Gastric cancer (GC) is one of the most virulent cancers in the world. Each year over 930,000 of people are diagnosed with GC and 700,000 die (2nd leading cause of death) worldwide. Patients with localized gastric cancer are most often treated surgery alone (in Asia) or surgery plus adjunct therapy (North America). This decision for treatment is empiric. There is no method to select a specific therapy or to avoid a specific one. Therefore, nearly all patients with AJCC/UICC stage II or III cancer are offered a similar treatment but their outcomes are unpredictable. We have considerable preliminary data that suggests a PCR-based practical prognostic signature (that allows us to compute a continuous "risk" score) for all pathologic stages is possible. Our main objective is to develop a PCR-based biomarker prognostic test for an "early" (= 12 months) recurrence-free survival (RFS) event for localized gastric cancer patients who undergo surgery with or without adjunct therapy. If the emerging prognostic signature has a high rate of accuracy (= 80%), alternate strategies can be developed to optimize treatment. Currently, we cannot optimize therapy and end up giving the same therapy to all patients with similar stage. Our overall goal is to validate previously identified prognostic gene signature in larger independent Asian GC patient cohort and Western GC patient cohorts, and improve the predictability of signatures by identifying more biomarkers to construct better prognostic signature and risk score.

Public Health Relevance

The overall goal of this proposal is to develop novel prognostic risk score that can predict the likelihood of early recurrence in gastric cancer patients. Our approach will pave the way for the optimization of patient treatments according to relative risk of patients. Currently, we cannot optimize therapy and end up giving the same therapy to all patients with similar stage.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA150229-04
Application #
8434159
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Thurin, Magdalena
Project Start
2010-04-05
Project End
2015-01-31
Budget Start
2013-02-01
Budget End
2015-01-31
Support Year
4
Fiscal Year
2013
Total Cost
$269,041
Indirect Cost
$98,762
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Lee, Hyun-Sung; Lee, Kwanbok; Jang, Hee-Jin et al. (2014) Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget 5:3472-81
Cho, Jae Yong; Lim, Jae Yun; Cheong, Jae Ho et al. (2011) Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 17:1850-7
Shah, Manish A; Ajani, Jaffer A (2010) Gastric cancer--an enigmatic and heterogeneous disease. JAMA 303:1753-4
Kim, Soo Mi; Park, Yun-Yong; Park, Eun Sung et al. (2010) Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 5:e15074